Earnings Call Summary | Predictive Oncology(POAI.US) Q4 2023 Earnings Conference
Earnings Call Summary | Predictive Oncology(POAI.US) Q4 2023 Earnings Conference
The following is a summary of the Predictive Oncology Inc. (POAI) Q4 2023 Earnings Call Transcript:
以下是預測腫瘤學公司（POAI）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Predictive Oncology's cash and cash equivalents ended at $8.7 million for Q4 2023, down from $22.1 million at the end of 2022.
The company experienced a decline in stockholders' equity to $8.3 million from $21.8 million as of December 31, 2022.
Net loss per share in 2023 reduced to $3.48, a decrease of approximately 50% from the previous year.
The firm generated a revenue of $1.8 million in 2023, with the Eagan operating segment being the major contributor.
預測腫瘤學的現金和現金等價物在2023年第四季度收於870萬美元，低於2022年底的2210萬美元。
該公司的股東權益從截至2022年12月31日的2180萬美元下降至830萬美元。
2023年每股淨虧損降至3.48美元，比上年下降約50％。
該公司在2023年創造了180萬美元的收入，其中伊根運營部門是主要貢獻者。
Business Progress:
業務進展：
Predictive Oncology advanced in the development of its PEDAL platform, enabling accurate predictions on drug responses to tumors.
In 2023, the company collaborated with reputable entities like Cancer Research Horizons, UPMC Magee-Women's Hospital, and Cvergenx.
The company plans a proposal to the Center for the Advancement of Science in Space and aims to use its developed technology on the space station.
In partnership with FluGen, Predictive Oncology secured a Phase 2B grant from NIH to develop a flu vaccine.
The company is set to announce a co-marketing venture with Fuji for endotoxin detection and treatments.
Predictive Oncology intends to increase its visibility in 2024 by attending industry conferences to attract collaborators and investors.
預測腫瘤學在其 PEDAL 平台的開發方面取得了進展，可以準確預測藥物對腫瘤的反應。
2023年，該公司與癌症研究視野、UPMC Magee-Women's Hospital和Cvergenx等知名機構合作。
該公司計劃向太空科學促進中心提交一份提案，目標是在空間站上使用其開發的技術。
預測腫瘤學與FluGen合作，獲得了美國國立衛生研究院的2B期撥款，用於開發流感疫苗。
該公司將宣佈與富士合作進行內毒素檢測和治療。
預測腫瘤學計劃通過參加行業會議來吸引合作者和投資者，從而在2024年提高其知名度。
More details: Predictive Oncology IR
更多詳情： 預測性腫瘤學 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。